GSK Eyes Quick Review of Gonorrhea Shot as Cases Multiply (1)

GSK Plc’s experimental gonorrhea vaccine got fast-track designation from US regulators, putting the shot in position to become the first preventive for a common, often-undetected infection that’s gaining resistance to treatment.

The Food and Drug Administration status makes the drug eligible for a sped-up approval process, if an ongoing mid-stage trial shows it’s effective, the company said Tuesday. GSK learned of its status in April and plans to move the vaccine to final-stage testing in 2026, said Giulia Giordano, vaccine development leader for the project.

In 2020, some 82 million people worldwide caught gonorrhea, a sexually transmitted infection ...